In this interview we discuss new data on the use of radiotherapy in cancer patients with brain metastases.

In this interview we discuss the effect of the gut microbiome on responses and survival outcomes in metastatic melanoma patients treated with anti–PD-1 immunotherapies.

In this interview we discuss how relapse in multiple myeloma manifests and treatment options for relapsed/refractory patients.

Dr. Karen Reckamp talks about ways to incorporate biomarkers for the treatment of lung cancer with immunotherapy into clinical practice at the 2017 American Society of Clinical Oncology Annual Meeting, held June 2–6 in Chicago.

As part of our coverage of the 2017 ASCO Annual Meeting, we discuss homologous recombination deficiency in ovarian cancer and PARP inhibitors.

In this interview we discuss decision making in the treatment of metastatic renal cell carcinoma.

In this interview ahead of ASCO 2017 we discuss the physical and cognitive effects of androgen deprivation therapy in older men treated for prostate cancer.

Ahead of the 2017 ASCO Annual Meeting, we discuss the discontinuation of TKIs in some chronic myeloid leukemia patients.

Ahead of the 2017 ASCO Annual Meeting, we discuss how to approach treatment for older patients with lung cancer.

In this interview we discuss important developments in the diagnosis and management of breast cancer and more.

In this interview we discuss a study that looked at the effect of an 8-week exercise intervention on treatment side effects for patients with prostate cancer.

In this interview we discuss pain management for cancer patients who are at high risk of opioid abuse.

In this interview we discuss humanistic medicine and some of the skills that physicians need in order to have open communication with their cancer patients, which can improve the quality of cancer care.

In this interview we discuss long-term data on the anti–PD-L1 immunotherapy atezolizumab in metastatic triple-negative breast cancer.

In this interview we discuss the use of CTCs and circulating tumor DNA for prognosis and disease monitoring in patients with breast cancer.

In this interview we discuss ASCO's first trial, TAPUR (Targeted Agent and Profiling Utilization Registry), which is examining 17 different commercially available drugs in settings outside of their indication.

In this interview we discuss the idea behind an enhanced recovery program for patients undergoing cytoreductive surgery for ovarian cancer, as well as some of the potential cost savings.

In this interview we discuss the approach to treating cancer in lesbian, gay, bisexual, transgender, and queer (LGBTQ) patients.

In this interview we discuss the latest therapy developments in the treatment of multiple myeloma.

In this interview we discuss clinical developments in essential thrombocythemia, polycythemia vera, and myelofibrosis, as well as the latest treatment options.

In this interview we discuss a new study that looked at the outcomes of patients with small renal masses who were followed with active surveillance.

In this interview we discuss a study that found that survivors of thyroid cancer diagnosed with the disease at a young age had an increased risk of late effects from therapy.

In this interview we discuss the latest clinical news in urothelial carcinoma, what we’ve learned about the biology of these tumors, and how treatment of this disease has evolved.

Ahead of the 2017 ASCO Gastrointestinal Cancer Symposium in San Francisco, we spoke with Dr. Geoffrey Ku on the advances in systemic therapy for esophageal and gastric cancer.

In this interview we discuss a recent study that found that more than half of patients with locally advanced cervical cancer in the United States did not receive standard of care.

In this interview we discuss what needs to change in order to combat the negative health impact of tobacco use and what academic institutions and researchers can do to diminish the use of tobacco products.

In this interview we discuss the use of liquid biopsies in lung cancer, the pros and cons compared with tissue biopsies, and how they can be used to help make treatment decisions.

In this interview we discuss breast cancer prevention and risk assessments, including the questions these assessments aim to answer, what classifies someone as average or high risk, and appropriate next steps for patients who fall in these categories.

In this interview we discuss prognostic models that may be able to predict disease progression in patients with chronic lymphocytic leukemia treated with the targeted agent ibrutinib.

As part of our coverage of the ASH Annual Meeting, we are discussing novel agents and strategies for relapsed/refractory Hodgkin lymphoma.